Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

The Trump administration announced it will not finalize a rule proposed by the Biden administration that would have allowed ...

President Trump will introduce a "most favored nation" plan aimed at cutting Medicare drug prices by linking them to the ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

Trump signs executive order, discussed "overweight" friend who was taking the "fat shot drug." It wasn't confirmed whether he ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Patients taking Eli Lilly’s drug to combat obesity, Zepbound, lost more weight than those who took Novo Nordisk’s Wegovy in a ...

Millions of Americans fighting obesity faced a setback last month when the Trump administration declined to allow Medicare and Medicaid to cover popular weight loss drugs like Wegovy and Zepbound. The ...